Kura Oncology, Inc.
BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE

Last updated:

Abstract:

The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.

Status:
Application
Type:

Utility

Filling date:

13 Jul 2020

Issue date:

15 Apr 2021